Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Beam Therapeutics
ISIN US07373V1052
|WKN A2PY7P
Market cap (in EUR)
1,537.09 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 1,537.09 m |
| EPS, EUR | -4.30 |
| P/B ratio | 1.54 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 58.72 m |
| Net income, EUR | -348.29 m |
| Profit margin | -593.13% |
What ETF is Beam Therapeutics in?
There are 37 ETFs which contain Beam Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Beam Therapeutics is the ARK Genomic Revolution UCITS ETF USD Accumulating.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.